Kang L Cheng

US Patent:

6680340, Jan 20, 2004

Filed:

Feb 13, 2003

Appl. No.:

10/344591

Inventors:

Kang Cheng - Bridgewater NJ
Samuel D. Wright - Westfield NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 3124

US Classification:

514539, 514563, 514619, 514459, 549416, 560 43, 560167, 560455

Abstract:

This invention provides a drug combination comprised of a thyroid hormone receptor beta agonist with a fibrate in therapeutically effective amounts, which is useful for reducing cholesterol synthesis, lowering plasma cholesterol levels and lowering plasma triglyceride levels.

US Patent:

6736783, May 18, 2004

Filed:

Mar 14, 2001

Appl. No.:

09/808449

Inventors:

Kevin R. Blake - Green Brook NJ
Kang Cheng - Bridgewater NJ
Glenn A. Clarke - Flemington NJ
Gary S. Kath - Scotch Plains NJ
Gregory W. King - Carteret NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61B 500

US Classification:

600582, 604327, 600575

Abstract:

An apparatus and process for automatically, repetitively sampling blood from conscious animals. The apparatus can simultaneously extract blood from a number of conscious, catherized animals at programmable time intervals. The apparatus is characterized as a system of computer controlled valves and pumps connected by tubing filled with saline solution to a catherized animal. Blood samples are collected via a cannula from the animal and placed in a fraction collector for analyses.

US Patent:

20040229844, Nov 18, 2004

Filed:

May 13, 2004

Appl. No.:

10/844773

Inventors:

Kang Cheng - Bridgewater NJ, US
M. Waters - Westfield NJ, US
Kathleen Metters - Montreal, CA
Gary O'Neill - Dollard-des-Ormeaux, CA

International Classification:

A61K031/69
A61K031/4745
A61K031/403

US Classification:

514/064000, 514/291000, 514/411000

Abstract:

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

US Patent:

20090233977, Sep 17, 2009

Filed:

May 21, 2009

Appl. No.:

12/470049

Inventors:

Kang Cheng - Bridgewater NJ, US
M. Gerard Waters - Westfield NJ, US
Kathleen M. Metters - Montreal, CA
Gary O'Neill - Dollard-des-Ormeaux, CA

International Classification:

A61K 31/403
A61P 3/06
A61P 3/00
A61P 9/10

US Classification:

514411

Abstract:

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

US Patent:

20100076002, Mar 25, 2010

Filed:

Nov 30, 2009

Appl. No.:

12/627787

Inventors:

Kang Cheng - Bridgewater NJ, US
M. Gerard Waters - Westfield NJ, US
Kathleen M. Metters - Montreal, CA
Gary O'Neill - Dollard-des-Ormeaux, CA

International Classification:

A61K 31/505
A61K 31/4406
A61K 31/47
A61P 3/00
A61P 9/10

US Classification:

514275, 514356, 514311

Abstract:

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.

US Patent:

20110118292, May 19, 2011

Filed:

Jan 24, 2011

Appl. No.:

13/012696

Inventors:

Kang Cheng - Bridgewater NJ, US
M. Gerard Waters - Westfield NJ, US
Kathleen M. Metters - Montreal, CA
Gary O'Neill - Dollard-des-Ormeaux, CA

International Classification:

A61K 31/455
A61K 31/47
A61K 31/505
A61P 9/10
A61P 3/06
A61P 3/00

US Classification:

514275, 514356, 514311

Abstract:

A method of treating atherosclerosis is disclosed wherein nicotinic acid or another nicotinic acid receptor agonist is administered to the patient in combination with a DP receptor antagonist. The DP receptor antagonist is administered to reduce, prevent or eliminate flushing that may otherwise occur.